Skip to main content
OpenTrials
Completed

NCT Number: NCT00693706

Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix

The purpose of the study is to compare the safety of & immune response to a single dose of GSK Biologicals' cell-culture based influenza vaccine 138842A with that of a US licensed, egg-based trivalent influenza vaccine [Fluarix] in healthy adults.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Influenza Infections Influenza, Human Orthomyxoviridae Infections RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year–49 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

GSK Investigational Site, Miami, Florida, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects who the investigator believes can and will comply with the requirements of the protocol
  • A male or non-pregnant, non-lactating female between 18 and 49 years of age at the time of vaccination
  • Access to a telephone for scheduled follow-up telephone contacts
  • Ability to provide written informed consent
  • Healthy subjects as established by medical history and physical examination before entering into the study
  • If the subject is female, she must be of non-childbearing potential, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination and continue such precautions for 2 months after receipt of the study vaccine. All women will have a pregnancy test on the day of vaccination.

Exclusion criteria

  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the dose of study vaccine, or planned use during the study period
  • Receipt of systemic glucocorticoids within 30 days of study enrollment
  • Administration of immunosuppressant, cytotoxic, or other immune-modifying drugs (other than glucocorticoids) or irradiation within 6 months prior to study enrollment or planned administration during the study period
  • Administration of immunoglobulins and/or blood products within 3 months prior to study enrollment or planned administration during the study period
  • Previous vaccination against influenza (2007-2008 influenza season)
  • History of anaphylactic or other allergic reaction to influenza vaccine, any other vaccine, or any vaccine component or excipient
  • History of Guillain-Barre Syndrome (GBS)
  • Acute disease, febrile illness, or upper respiratory infection at screening.
  • History of splenectomy
  • Any confirmed or suspected, acquired, congenital, or hereditary immunodeficiency or immunosuppressive condition (including human immunodeficiency virus [HIV]) based on medical history and physical examination
  • Acquired or congenital coagulation disorders or known thrombocytopenia
  • Current treatment with warfarin or heparin derivatives
  • Known use of an analgesic or antipyretic medication within 12 hours prior to treatment for the purposes of prophylaxis of adverse events
  • Any medical condition for which the US Advisory Committee on Immunization Practices recommends vaccination against influenza

Treatment and study plan

Trivalent influenza vaccine GSK 138842A

Biological

IM injection on Day 0

Fluarix

Biological

IM injection on Day 0

Primary outcomes

  1. Number of Subjects With Solicited Local Symptoms.

    Time frame: During the 7-day (Days 0-6) post vaccination period

    Solicited local symptoms were pain, redness and swelling at the injection site. Any = occurrence of a symptom regardless of intensity.

  2. Number of Subjects With Solicited General Symptoms.

    Time frame: During the 7-day (Days 0-6) post vaccination period

    Solicited general symptoms were arthralgia, fatigue, headache, muscle aches, shivering and temperature, assessed as oral temperature above or equal (≥) 38.0 degrees Celsius (°C). Any = occurrence of a symptom regardless of intensity or relationship to vaccination.

  3. Number of Subjects With Medically Attended Adverse Events (MAEs).

    Time frame: During the entire study period (Days 0-182)

    Medically-attended events (MAEs) refer to non-serious and serious events leading to an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits and hospitalization. Related MAE = MAE assessed by the investigator as related to the vaccination.

  4. Number of Subjects With New Onset of Chronic Diseases (NOCDs).

    Time frame: During the entire study period (Days 0-182)

    NOCDs include conditions such as autoimmune disorders, asthma, type I diabetes, or allergies.

  5. Number of Subjects With Unsolicited Adverse Events (AEs).

    Time frame: During the 90-day (Days 0-89) post-vaccination period

    Unsolicited AEs cover any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any unsolicited AE = any unsolicited AE regardless of intensity or relationship to vaccination.

  6. Number of Subjects With Serious Adverse Events (SAEs).

    Time frame: During the entire study period (Days 0-182)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any SAE = any SAE regardless of intensity or relationship to vaccination.

  7. Titers for Serum Hemagglutination Inhibition (HI) Antibodies for 3 Strains of Influenza Disease.

    Time frame: At Day 21

    Titers are presented as geometric mean titers (GMTs). The 3 influenza strains assessed were A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2) and B/Malaysia/2506/2004 (MALAY.)

  8. Number of Seroprotected Subjects Against 3 Strains of Influenza Disease.

    Time frame: At Day 21

    A seroprotected subject was defined as a vaccinated subject with a serum HI antibody titer ≥ 1:40, a level of HI antibody that has been viewed as correlating with protection against influenza. The 3 influenza strains assessed were A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2) and B/Malaysia/2506/2004 (MALAY.)

  9. Number of Seroconverted Subjects Against 3 Strains of Influenza Disease.

    Time frame: At Day 21

    A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer <1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 3 influenza strains assessed were A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2) and B/Malaysia/2506/2004 (MALAY.)

  10. Geometric Mean Fold-rise (GMFR) in 3 Strains of Influenza Disease.

    Time frame: At Day 0 and Day 21

    GMFR was defined as the geometric mean of the ratio of the post-vaccination inverse HI titer to the Day 0 inverse HI titer. The 3 influenza strains assessed were A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2) and B/Malaysia/2506/2004 (MALAY.)

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

Safety and Immunogenicity Study of GSK Biologicals' Cell Culture-based Influenza Virus Vaccine 1388442A Compared With US Licensed TIV in Healthy Adults

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Jun 9, 2008
Registry last updated
Jun 8, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.